SinoMab: First-ever homegrown firm to take advantage of new rules that allow pre-revenue biotech firms to list on the stock exchange

First-ever homegrown firm to take advantage of new rules that allow pre-revenue biotech firms to list on the stock exchange

An antibody maker based in Hong Kong has filed for an IPO on the HKEX, marking the first-ever homegrown firm to reap benefits out of new rules that allow pre-revenue biotech firms to list on the stock exchange.

The Chief Executive Officer, as well as, founder called SinoMab as the industry leader in the region, having begun in 2002 & with support from Morningside at a time when the leaders of the city appeared to be more interested in the rationalization of Chinese medicine. An Oxford-graduated local who took training in the United States as a postdoc and then at Immunomedics, Leung, started his own framework for humanizing antibodies. That formed the basis of existing pipeline of SinoMab, which constitutes of a BTK inhibitor, a lead anti-CD22 drug, and 4 other preclinical mAbs.

SinoMab is targeting some of the biggest indications in immunology with SM03 like systemic lupus erythematosus, rheumatoid arthritis, and Sjogren’s syndrome, in addition to non-Hodgkin’s lymphoma.

While Leung has kept the headquarters of the firm in Hong Kong’s Science Park, has also expanded SinoMab’s footprint by opening an office in Shenzhen, a production plant in Hainan & a subsidiary in Australia for facilitating the clinical trials.

He stated in an interview 2 years ago with Pharma Boardroom that in the future, we are expecting to lean more towards China since we can increasingly see that the talent, the market, and money lie there. As we look forward to positioning ourselves for market approval, we are presently investing in a fresh manufacturing plant in China & there’s a need for channeling to source the money for that. An extended presence in China will also help us in expanding our portfolio & gaining more collaboration, both on a local & global level.